Qiagen has announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation.
These systems are designed to deliver new levels of efficiency and sustainability for laboratories worldwide and address different customer segments.
QIAsymphony Connect, which marks the next generation of the flagship QIAsymphony with over 3,300 cumulative placements, is progressing well toward a phased launch to selected customers starting in 2025.
The QIAsymphony Connect addresses pathogen nucleic acid extraction and various other applications including liquid biopsy, a non-invasive method for detecting cancer and other diseases through blood samples, as well as oncology, genomics, and clinical research workflows. The system can process up to 96 samples at a time and features improved automation capabilities for sample tracking and new applications, higher yield for increase in assay sensitivity and digital connectivity.
QIAsprint Connect, on track for launch in 2026, marks the entry of Qiagen into automated high-throughput sample processing. The system supports a wide range of sample types, such as plant, microbial, soil, stool and human tissues, and is already being used to develop nine different applications.
QIAmini, also on track for launch in 2026, expands Qiagen’s automation portfolio into the low-throughput segment. This cost-effective and low-complexity entry into automation brings the reliability of Qiagen trusted kits to smaller labs and batch sizes. Ideal for replacing tedious pipetting, it delivers the reproducibility of automation with the flexibility to scale as needed.
